[go: up one dir, main page]

DE602004024536D1 - Hemmung der tumor-angiogenese durch eine kombination von thrombospondin-1 und hemmern des vaskulären endothel-wachstumsfaktors - Google Patents

Hemmung der tumor-angiogenese durch eine kombination von thrombospondin-1 und hemmern des vaskulären endothel-wachstumsfaktors

Info

Publication number
DE602004024536D1
DE602004024536D1 DE602004024536T DE602004024536T DE602004024536D1 DE 602004024536 D1 DE602004024536 D1 DE 602004024536D1 DE 602004024536 T DE602004024536 T DE 602004024536T DE 602004024536 T DE602004024536 T DE 602004024536T DE 602004024536 D1 DE602004024536 D1 DE 602004024536D1
Authority
DE
Germany
Prior art keywords
hgf
tsp
angiogenesis
expression
vegf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004024536T
Other languages
English (en)
Inventor
Yu-Wen Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Van Andel Research Institute
Original Assignee
Van Andel Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Van Andel Research Institute filed Critical Van Andel Research Institute
Publication of DE602004024536D1 publication Critical patent/DE602004024536D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE602004024536T 2003-07-07 2004-07-07 Hemmung der tumor-angiogenese durch eine kombination von thrombospondin-1 und hemmern des vaskulären endothel-wachstumsfaktors Expired - Lifetime DE602004024536D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48467603P 2003-07-07 2003-07-07
PCT/US2004/021641 WO2005007193A2 (en) 2003-07-07 2004-07-07 Inhibition of tumor angiogenesis by combination of thrombospondin-1 and inhibitors of vascular endothelial growth factor

Publications (1)

Publication Number Publication Date
DE602004024536D1 true DE602004024536D1 (de) 2010-01-21

Family

ID=34079062

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004024536T Expired - Lifetime DE602004024536D1 (de) 2003-07-07 2004-07-07 Hemmung der tumor-angiogenese durch eine kombination von thrombospondin-1 und hemmern des vaskulären endothel-wachstumsfaktors

Country Status (6)

Country Link
US (1) US20070020234A1 (de)
EP (1) EP1648493B1 (de)
AT (1) ATE451115T1 (de)
CA (1) CA2539190A1 (de)
DE (1) DE602004024536D1 (de)
WO (1) WO2005007193A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040208876A1 (en) 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
DK1846406T5 (da) 2005-02-09 2011-10-31 Arqule Inc Maleimidderivater, farmaceutiske sammensætninger og fremgangsmåder til behandling af cancer
WO2006105317A2 (en) * 2005-03-30 2006-10-05 Abbott Laboratories Antitumorigemic drug combination comprising a vegf-inhibitor and a thrombospondin-1 peptidomimetic
EP1907856A2 (de) * 2005-07-27 2008-04-09 Oncomethylome Sciences SA Hemmung der angiogenese basiert auf icam 1 oder junb expressionsrate
CA2619654A1 (en) * 2005-08-24 2007-03-01 Cell Matrix Combination therapies for inhibiting integrin-extracellular matrix interactions
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
JP2010530885A (ja) 2007-06-22 2010-09-16 アークル インコーポレイテッド キナゾリノン化合物およびその使用方法
EP2392574B1 (de) 2007-06-22 2013-12-18 ArQule, Inc. Indolylpyrrolidine zur Behandlung von Krebs
CN101801961B (zh) 2007-06-22 2014-09-24 艾科尔公司 吡咯烷酮、吡咯烷-2,5-二酮、吡咯烷和硫代琥珀酰亚胺衍生物、组合物以及治疗癌症的方法
US20120039798A1 (en) * 2009-03-02 2012-02-16 University Of Rochester Methods of modifying p53 acetylation and treating cancer using avra
US20130315895A1 (en) 2010-07-01 2013-11-28 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
US20180057595A1 (en) 2015-03-16 2018-03-01 Celldex Therapeutics, Inc. Anti-MET Antibodies and Methods of Use Thereof
US10548765B2 (en) * 2017-06-09 2020-02-04 Kali Care, Inc. Universal modular attachments for eye drop containers
KR20200119539A (ko) * 2019-04-10 2020-10-20 가톨릭대학교 산학협력단 간암의 예방 또는 치료용 조성물
CN119077148B (zh) * 2024-08-29 2025-09-23 华中科技大学 一种基于势场蚁群算法的防碰撞激光切割路径优化方法及系统

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837676A (en) * 1993-10-18 1998-11-17 Long Island Jewish Medical Center Use of scatter factor to enhance angiogenesis
US5639725A (en) * 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein
US5707624A (en) * 1994-06-03 1998-01-13 The Regents Of The University Of Michigan Treatment of Kaposi's sarcoma by inhibition of scatter factor
AU2795499A (en) * 1998-02-26 1999-09-15 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Conjugated suramin or derivatives thereof with peg, polyaspartate or polyglutamate for cancer treatment
US6576632B1 (en) * 1999-08-27 2003-06-10 Pfizer Inc Biaryl compounds useful as anticancer agents
US6849599B2 (en) * 2000-03-08 2005-02-01 Rhode Island Hospital Combination drug therapy
CA2410485A1 (en) * 2000-05-26 2001-12-06 Beth Israel Deaconess Medical Center Thrombospondin-1 type 1 repeat polypeptides
ES2243568T3 (es) * 2000-08-31 2005-12-01 F. Hoffmann-La Roche Ag 7-oxo-piridopirimidinas.
BR0113628A (pt) * 2000-08-31 2003-07-01 Hoffmann La Roche 7-oxo-piridopirimidinas como inibidores de uma proliferação celular
AU2002255852B2 (en) * 2001-03-22 2006-11-09 Van Andel Research Institute Anthrax lethal factor inhibits tumor growth and angiogenesis
JP2003012541A (ja) * 2001-06-07 2003-01-15 Daiichi Fine Chemical Co Ltd 血管新生阻害剤
US6906036B2 (en) * 2001-08-16 2005-06-14 Kimberly-Clark Worldwide, Inc. Anti-aging and wound healing compounds
JP3913542B2 (ja) * 2001-12-17 2007-05-09 独立行政法人理化学研究所 血管新生阻害作用を有する新規物質
JP2005533748A (ja) * 2002-03-08 2005-11-10 シグナル ファーマシューティカルズ，インコーポレイテッド 増殖性障害および癌を治療、予防、または管理するための併用療法

Also Published As

Publication number Publication date
CA2539190A1 (en) 2005-01-27
EP1648493B1 (de) 2009-12-09
EP1648493A2 (de) 2006-04-26
US20070020234A1 (en) 2007-01-25
WO2005007193A2 (en) 2005-01-27
WO2005007193A3 (en) 2005-06-30
ATE451115T1 (de) 2009-12-15

Similar Documents

Publication Publication Date Title
DE602004024536D1 (de) Hemmung der tumor-angiogenese durch eine kombination von thrombospondin-1 und hemmern des vaskulären endothel-wachstumsfaktors
Eberhardt et al. The role of the PAX8/PPARγ fusion oncogene in the pathogenesis of follicular thyroid cancer
Dutta et al. Leptin and cancer: Pathogenesis and modulation
Dennler et al. Induction of sonic hedgehog mediators by transforming growth factor-β: Smad3-dependent activation of Gli2 and Gli1 expression in vitro and in vivo
Bardet et al. Characterization of oestrogen receptors in zebrafish (Danio rerio)
Bolós et al. The dual kinase complex FAK-Src as a promising therapeutic target in cancer
Meng et al. p53-independent upregulation of KILLER/DR5 TRAIL receptor expression by glucocorticoids and interferon-γ
Barr et al. Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions
Weeraratna et al. Pan-trk inhibition decreases metastasis and enhances host survival in experimental models as a result of its selective induction of apoptosis of prostate cancer cells
Bigelow et al. Sonic hedgehog induces epidermal growth factor dependent matrix infiltration in HaCaT keratinocytes
Carmel et al. Peripheral-type benzodiazepine receptors in the regulation of proliferation of MCF-7 human breast carcinoma cell line
Montano et al. Epidermal growth factor, neurotrophins and the metastatic cascade in prostate cancer
Alcedo et al. Imatinib mesylate as treatment for adenoid cystic carcinoma of the salivary glands: report of two successfully treated cases
Arrieta et al. Hepatocyte growth factor is associated with poor prognosis of malignant gliomas and is a predictor for recurrence of meningioma
Chen et al. Interleukin-32α inactivates JAK2/STAT3 signaling and reverses interleukin-6-induced epithelial–mesenchymal transition, invasion, and metastasis in pancreatic cancer cells
Lei et al. Exogenous hydrogen sulfide exerts proliferation, anti-apoptosis, angiopoiesis and migration effects via activating HSP90 pathway in EC109 cells
DE69930835D1 (de) Bicyclische pyridin-und pyrimidinderivate als neuropeptid y rezeptorantagonisten
Venuti et al. Expression of endothelin 1 and endothelin A receptor in HPV‐associated cervical carcinoma: new potential targets for anticancer therapy
Fulda Therapeutic opportunities based on caspase modulation
Baldini et al. The urokinase plasminogen activating system in thyroid cancer: clinical implications
Dieudonné et al. High Wnt signaling represses the proapoptotic proteoglycan syndecan-2 in osteosarcoma cells
Ng et al. cDNA microarray analysis of early gene expression profiles associated with hepatitis B virus X protein-mediated hepatocarcinogenesis
Jung et al. Recombinant Erdr1 suppresses the migration and invasion ability of human gastric cancer cells, SNU-216, through the JNK pathway
Xie Hedgehog signaling pathway: development of antagonists for cancer therapy
Blinova et al. Novel aminochromone derivative inhibits tumor growth on xenograft model of lung cancer in mice

Legal Events

Date Code Title Description
8364 No opposition during term of opposition